Best Practice & Research Clinical Endocrinology & Metabolism
Volume 24, Issue 1 , Pages 51-61 , February 2010

Assessment of nodular goitre

References 

  1. Wiersinga WM. Management of non-toxic multinodular goiter. 1st edn In:  Wass JAH,  Shalet SM editor. Endocrinology and diabetes. New York: Oxford University Press; 2000;p. 557–564
  2. Wang C, Crapo LM. The epidemiology of thyroid disease and implications for screening. Endocrinology and Metabolism Clinics of North America. 1997;26:189–218
  3. Marqusee E, Benson CB, Frates MC, et al. Usefulness of ultrasonography in the management of nodular thyroid disease. Annals of Internal Medicine. 2000;133:696–700
  4. Knudsen N, Perrild H, Christiansen E, et al. Thyroid structure and size and two-year follow-up of solitary cold thyroid nodules in an unselected population with borderline iodine deficiency. European Journal of Endocrinology. 2000;142:224–230
  5. Aghini-Lombardi F, Antonangeli L, Martino E, et al. The spectrum of thyroid disorders in an iodine-deficient community: the Pescopagano survey. The Journal of Clinical Endocrinology and Metabolism. 1999;84:561–566
  6. TunbridgeWM , Evered DC, Hall R, et al. The spectrum of thyroid disease in a community: the Whickham survey. Clinical Endocrinology. 1977;7:481–493
  7. Vander JB, Gaston EA, Dawber TR. Significance of solitary nontoxic thyroid nodules. Preliminary report. The New England Journal of Medicine. 1954;251:970
  8. Baldwin DB, Rowett D. Incidence of thyroid disorders in Connecticut. The Journal of the American Medical Association. 1978;239:742–744
  9. Jarløv AE, Hegedüs L, Gjørup T, et al. Observer variation in the clinical assessment of the thyroid gland. Journal of Internal Medicine. 1991;229:159–161
  10. Tan GH, Gharib H. Thyroid incidentalomas: management approaches to nonpalpable nodules discovered incidentally on thyroid imaging. Annals of Internal Medicine. 1997;126:226–231
  11. Belfiore A, La Rosa GL, La Porta GA, et al. Cancer risk in patients with cold thyroid nodules: relevance of iodine intake, sex, age, and multinodularity. American Journal of Medicine. 1992;93:363–369
  12. Krohn K, Paschke R. Progress in understanding the etiology of thyroid autonomy. The Journal of Clinical Endocrinology and Metabolism. 2001;86:3336–3345
  13. Baltisberger BL, Minder CE, Burgi H. Decrease of incidence of toxic nodular goiter in a region of Switzerland after full correction of mild iodine deficiency. European Journal of Endocrinology. 1995;132:546
  14. Lauberg P, Pedersen KM, Hreidarsson A, et al. Iodine intake and the pattern of thyroid disorders: a comparative epidemiological study of thyroid abnormalities in the elderly in Iceland and in Jutland, Denmark. The Journal of Clinical Endocrinology and Metabolism. 1998;83:765–769
  15. Bottcher Y, Eszlinger M, Tonjes A, et al. The genetics of euthyroid familial goiter. Trends in Endocrinology and Metabolism. 2005;314–319
  16. Hansen PS. Genetic and environmental causes of individual differences in thyroid size: a study of healthy Danish twins. The Journal of Clinical Endocrinology and Metabolism. 2004;89:2071–2077
  17. Brix TH, Kyvik KO, Hegedüs L. Major role of genes in the etiology of simple goiter in females: a population-based twin study. The Journal of Clinical Endocrinology and Metabolism. 1999;84:3071–3075
  18. Corral J, Martin C, Perez R, et al. Thyroglobulin gene point mutation associated with non-endemic simple goitre. Lancet. 1993;341:462–464
  19. Bignell GR, Canzian F, Shayeghi M, et al. Familial nontoxic multinodular thyroid goiter locus maps to chromosome 14q but does not account for familial nonmedullary thyroid cancer. American Journal of Human Genetics. 1997;61:1123–1130
  20. Neumann S, Willgerodt H, Ackermann F, et al. Linkage of familial euthyroid goiter to the multinodular goiter-1 locus and exclusion of the candidate genes thyroglobulin, thyroperoxidase, and Na_/I_ symporter. The Journal of Clinical Endocrinology and Metabolism. 1999;84:3750–3756
  21. McKay JD, Williamson J, Lesueur F, et al. At least three genes account for familial papillary thyroid carcinoma: TCO and MNG1 excluded as susceptibility loci from a large Tasmanian family. European Journal of Endocrinology. 1999;141:122–125
  22. Capon F, Tacconelli A, Giardina E, et al. G Mapping a dominant form of multinodular goiter to chromosome Xp22. American Journal of Human Genetics. 2000;67:1004–1007
  23. Dumont JE, Lamy F, Roger P, et al. Physiological and pathological regulation of thyroid cell proliferation and differentiation by thyrotropin and other factors. Physiological Reviews. 1992;72:667–697
  24. Parma J, Duprez L, Van Sande J, et al. Somatic mutations in the thyrotropin receptor gene cause hyperfunctioning thyroid adenomas. Nature. 1993;365:649–651
  25. Paschke R, Tonacchera M, Van Sande J, et al. Identification and functional characterization of two new somatic mutations causing constitutive activation of the TSH receptor in hyperfunctioning autonomous adenomas of the thyroid. The Journal of Clinical Endocrinology and Metabolism. 1994;79:1785–1789
  26. Van Sande J, Parma J, Tonacchera M, et al. Somatic and germline mutations of the TSH receptor gene in thyroid diseases. The Journal of Clinical Endocrinology and Metabolism. 1995;80:2577–2585
  27. Tonacchera M, Chiovato L, Pinchera A, et al. Hyperfunctioning thyroid nodules in toxic multinodular goiter share activating somatic thyrotropin receptor mutations with solitary toxic adenoma. The Journal of Clinical Endocrinology and Metabolism. 1998;83:492–498
  28. Krohn K, Fuhrer D, Bayer Y, et al. Molecular pathogenesis of euthyroid and toxic multinodular goiter. Endocrine Reviews. 2005;26:504–524
  29. Nogueira CR, Kopp P, Arseven OK, et al. Thyretropin receptor mutations in hyperfunctiong thyroid adenomas from Brazil. Thyroid. 1999;11:1063–1068
  30. Georgopoulos NA, Sykiotis GP, Sgourou A, et al. Autonomous functioning nodules in a former iodine deficient area commonly harbour gain-of-function mutations in the thyreotropin signaling pathway. European Journal of Endocrinology. 2003;149:287–292
  31. Palos Paz F, Perez Guerra O, Cameselle-Tejjeiro J, et al. Prevalence of mutations in TSHr, GNAS, PRKAR1A, and RAS genes in a large series of toxic thyroid adenomas from Galicia, an iodine-deficient area in NW Spain. European Journal of Endocrinology. 2008;159:623–631
  32. Gabriel EM, Bergert ER, Grant CS, et al. Germline polymorphisms of codon 727 of human thyretropin stimulating hormone receptor is associated with toxic multinodular goiter. The Journal of Clinical Endocrinology and Metabolism. 1999;84:3328–3335
  33. Takeshita A, Nagayama Y, Yokoyama N, et al. Rarity of oncogenic mutations in the thyrotropin receptor of autonomously functioning thyroid nodules in Japan. The Journal of Clinical Endocrinology and Metabolism. 1995;80:2607–2610
  34. Tonacchera M, Agretti P, Chiovato L, et al. Activating thyrotropin receptor mutations are present in nonadenomatous hyperfunctioning nodules of toxic or autonomous multinodular goiter. The Journal of Clinical Endocrinology and Metabolism. 2000;85:2270–2274
  35. Krohn K, Wohlgemuth S, Gerber H, et al. Hot microscopic areas of iodine-deficient euthyroid goiters contain constitutively activating TSH receptor mutations. The Journal of Pathology. 2000;192:37–42
  36. Refetoff S, Harrison J, Karanfilski BT, et al. Continuing occurrence of thyroid carcinoma after irradiation to the neck in infancy and childhood. The New England Journal of Medicine. 1975;292:171–175
  37. Shibata Y, Yamashita S, Masyakin VB, et al. 15 years after Chernobyl: new evidence of thyroid cancer. Lancet. 2001;358:1965–1966
  38. Bonnema SJ, Bennedbæk FN, Wiersinga WM, et al. Management of the nontoxic multinodular goitre: a European questionnaire study. Clinical Endocrinology. 2002;53:5–12
  39. Bonnema SJ, Bennedbæk FN, Ladenson PW, et al. Management of the nontoxic multinodular goiter: a North American survey. The Journal of Clinical Endocrinology and Metabolism. 2002;87:112–117
  40. Cohen R, Campos JM, Salaun C, et al. Preoperative calcitonin levels are predictive of tumor size and postoperative calcitonin normalization in medullary thyroid carcinoma. Groupe d'Etudes des Tumeurs a Calcitonine (GETC). The Journal of Clinical Endocrinology and Metabolism. 2000;85:919–922
  41. Meier CA. Thyroid nodules: pathogenesis, diagnosis and treatment. Baillière's Clinical Endocrinology and Metabolism. 2000;14:559–575
  42. Hahm JR, Lee MS, Min YK, et al. Routine measurement of serum calcitonin is useful for early detection of medullary thyroid carcinoma in patients with nodular thyroid diseases. Thyroid. 2001;11:73–80
  43. Vierhapper H, Raber W, Bieglmayer C, et al. Routine measurement of plasma calcitonin in nodular thyroid diseases. The Journal of Clinical Endocrinology and Metabolism. 1997;82:1589–1593
  44. Rieu M, Lame MC, Richard A, et al. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules. Clinical Endocrinology. 1995;42:453–460
  45. Niccoli P, Wion-Barbot N, Caron P, et al. Interest of routine measurement of serum calcitonin: study in a large series of thyroidectomized patients. The French Medullary Study Group. The Journal of Clinical Endocrinology and Metabolism. 1997;82:338–341
  46. Pacini F, Fontanelli M, Fugazzola L, et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic medullary thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism. 1994;78:826–829
  47. Ozgen AG, Hamulu F, Bayraktar F, et al. Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. Thyroid. 1999;9:579–582
  48. Knudsen N, Bols B, Bulow I, et al. Validation of ultrasonography of the thyroid gland for epidemiological purposes. Thyroid. 1999;9:1069–1074
  49. Wiest PW, Hartshorne MF, Inskip PD, et al. Thyroid palpation vs. high-resolution thyroid ultrasonography in the detection of nodules. Journal of Ultrasound in Medicine. 1998;17:487–496
  50. Ezzat S, Sarti DA, Cain DR, et al. Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Archives of Internal Medicine. 1994;154:1838–1840
  51. Vitti P, Rago T. Thyroid ultrasound as a predicator of thyroid disease. Journal of Endocrinological Investigation. 2003;26:686–689
  52. Rago T, Santini F, Scutari M, et al. Elastography: new developments in ultrasound for predicting malignancy in thyroid nodules. The Journal of Clinical Endocrinology and Metabolism. 2007;92:2917–2922
  53. Hays MT, Wesselossky B. Simultaneous measurement of thyroidal trapping (99 mTcO4-) and binding (131I-): clinical and experimental studies in man. Journal of Nuclear Medicine. 1973;14:785–792
  54. Kumar A, Ahuja MM, Chattopadhyay TK, et al. Fine needle aspiration cytology, sonography and radionuclide scanning in solitary thyroid nodule. The Journal of the Association of Physicians of India. 1992;40:302–306
  55. Loy TJ, Sundram FX. Diagnostic management of solitary thyroid nodules. Annals of the Academy of Medicine, Singapore. 1989;6:658–664
  56. Ashcraft MW, Van Herle AJ. Management of thyroid nodules. Scanning techniques, thyroid suppressive therapy, and fine needle aspiration. Head and Neck Surgery. 1981;3:297–322
  57. Christensen SB, Bondeson L, Ericsson UB, et al. Prediction of malignancy in the solitary thyroid nodule by physical examination, thyroid scan, fine-needle biopsy and serum thyroglobulin. A prospective study of 100 surgically treated patients. Acta Chirurgica Scandinavica. 1984;150:433–439
  58. Cox MR, Marshall SG, Spence RA. Solitary thyroid nodule: a prospective evaluation of nuclear scanning and ultrasonography. British Journal of Surgery. 1991;78:90–93
  59. Korun N, Asci C, Yilmazlar T, et al. Total thyroidectomy or lobectomy in benign nodular disease of the thyroid: changing trends in surgery. International Surgery. 1997;82:417–419
  60. Mazzaferri EL. Management of a solitary thyroid nodule. The New England Journal of Medicine. 1993;328:553–559
  61. Gharib H, Goellner JR, Zinsmeister AR, et al. Fine-needle aspiration biopsy of the thyroid. The problem of suspicious cytologic findings. Annals of Internal Medicine. 1994;101:25–28
  62. Leenhardt L, Hejblum G, Franc B, et al. Indications and limits of ultrasound-guided cytology in the management of nonpalpable thyroid nodules. The Journal of Clinical Endocrinology and Metabolism. 1999;84:24–28
  63. Danese D, Sciacchitano S, Farsetti A, et al. Diagnostic accuracy of conventional vs. sonography-guided fine-needle aspiration biopsy of thyroid nodules. Thyroid. 1998;8:15–21
  64. Carmeci C, Jeffrey RB, McDougall IR, et al. Ultrasound-guided fine-needle aspiration biopsy of thyroid masses. Thyroid. 1998;8:283–289
  65. Pelizzo MR, Bernante P, Toniato A, et al. Frequency of thyroid carcinoma in a recent series of 539 consecutive thyroidectomies for multinodular goiter. Tumori. 1997;83:653–655
  66. Tollin SR, Mery GM, Jelveh N, et al. The use of fine-needle aspiration biopsy under ultrasound guidance to assess the risk of malignancy in patients with a multinodular goiter. Thyroid. 2000;10:235–241
  67. Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. The Journal of Clinical Endocrinology and Metabolism. 2002;87:1941–1946
  68. Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology. 2007;148:936–941
  69. Nikiforova YE, Steward DL, Robinson-Smith , et al. Molecular testing for mutations in improving the fine needle aspiration diagnosis of thyroid nodules. The Journal of Clinical Endocrinology and Metabolism. 2009;94:2092–2098

PII: S1521-690X(09)00099-2

doi: 10.1016/j.beem.2009.08.008

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 24, Issue 1 , Pages 51-61 , February 2010

Article Tools